Efficacy and safety of proactive drug monitoring in inflammatory bowel disease treated with anti-TNF agents: A systematic review and meta-analysis

A systematic review and a meta-analysis of the literature was conducted to assess efficacy and safety of proactive therapeutic drug monitoring (TDM) versus conventional management during maintenance treatment with anti-tumour necrosis factor (anti-TNFα) in patients with inflammatory bowel disease (I...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease Vol. 56; no. 3; pp. 421 - 428
Main Authors: Manceñido Marcos, Noemí, Novella Arribas, Blanca, Mora Navarro, Gustavo, Rodríguez Salvanés, Francisco, Loeches Belinchón, Pilar, Gisbert, Javier P.
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 01-03-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A systematic review and a meta-analysis of the literature was conducted to assess efficacy and safety of proactive therapeutic drug monitoring (TDM) versus conventional management during maintenance treatment with anti-tumour necrosis factor (anti-TNFα) in patients with inflammatory bowel disease (IBD). A search was conducted up to January 2022 (MEDLINE, EMBASE, and the Cochrane Library). The primary outcome was the ability to maintain clinical remission at 12 months. The certainty of evidence was determined using the GRADE approach. Nine studies were identified: one systematic review, six randomised clinical trials, and two cohort studies. No superior efficacy of proactive TDM [relative risk 1.16; 95% confidence interval (CI): 0.98–1.37, n=528; I2=55%] was shown. Proactive TDM could improve the durability of anti-TNFα treatment [odds ratio (OR) 0.12; 95%CI: 0.05–0.27; n=390; I2=45%), prevent acute infusion reactions (OR 0.21; 95%CI: 0.05–0.82; n=390; I2=0%), decrease adverse events (OR 0.38; 95%CI: 0.15–0.98; n=390; I2=14%), and reduce the probability of surgery, at lower economical expenditure. The analysed evidence did not confirm the superiority of proactive TDM of anti-TNFα treatment over conventional management in patients with IBD, so proactive TDM should not currently be recommended.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1590-8658
1878-3562
1878-3562
DOI:10.1016/j.dld.2023.06.028